603127 昭衍新药
已收盘 02-02 15:00:00
资讯
新帖
简况
每周股票复盘：昭衍新药（603127）股东周志文减持1497.9万股
证券之星 · 02-01 01:49
每周股票复盘：昭衍新药（603127）股东周志文减持1497.9万股
AI重塑医药生产力，为何超六成医药企业拥抱钉钉？
上观新闻 · 01-30
AI重塑医药生产力，为何超六成医药企业拥抱钉钉？
昭衍新药：周志文已减持1497.90万股
南方财经网 · 01-29
昭衍新药：周志文已减持1497.90万股
实验猴涨价推动昭衍新药业绩反转，预计2025年扣非净利同比增长超9倍
每日经济新闻 · 01-26
实验猴涨价推动昭衍新药业绩反转，预计2025年扣非净利同比增长超9倍
每周股票复盘：昭衍新药（603127）股东周志文减持1010.37万股
证券之星 · 01-25
每周股票复盘：昭衍新药（603127）股东周志文减持1010.37万股
1月23日昭衍新药现2笔折价12.81%的大宗交易 合计成交2.13亿元
证券之星 · 01-23
1月23日昭衍新药现2笔折价12.81%的大宗交易 合计成交2.13亿元
去年四季度买回昭衍新药、中国东航，中欧基金葛兰：一季度医药板块有望延续结构性行情
澎湃新闻 · 01-22
去年四季度买回昭衍新药、中国东航，中欧基金葛兰：一季度医药板块有望延续结构性行情
富贵猴中求？实验猴价格涨至15万元一只，昭衍新药净利润预增超214%
时代财经 · 01-21
富贵猴中求？实验猴价格涨至15万元一只，昭衍新药净利润预增超214%
昭衍新药：公司具备OECD的GLP认证资质，可以承接相关非临床服务项目
证券日报 · 01-20
昭衍新药：公司具备OECD的GLP认证资质，可以承接相关非临床服务项目
昭衍新药：2025年净利同比预增214%~371%
每日经济新闻 · 01-20
昭衍新药：2025年净利同比预增214%~371%
昭衍新药：公司不涉及脑机接口业务
证券日报 · 01-13
昭衍新药：公司不涉及脑机接口业务
每周股票复盘：昭衍新药（603127）拟注销129,114股A股
证券之星 · 01-11
每周股票复盘：昭衍新药（603127）拟注销129,114股A股
港股异动 | 昭衍新药(06127)涨超7% 近一月股价累涨近六成 公司有望受益猴价公允价值收益
智通财经 · 01-09
港股异动 | 昭衍新药(06127)涨超7% 近一月股价累涨近六成 公司有望受益猴价公允价值收益
港股异动 | 昭衍新药(06127)再涨超4% 实验猴供需缺口或不断拉大 公司拥有优质稀缺实验猴资源
智通财经 · 01-08
港股异动 | 昭衍新药(06127)再涨超4% 实验猴供需缺口或不断拉大 公司拥有优质稀缺实验猴资源
昭衍新药（603127）披露员工持股计划回购股份注销实施公告，1月6日股价下跌0.16%
证券之星 · 01-06
昭衍新药（603127）披露员工持股计划回购股份注销实施公告，1月6日股价下跌0.16%
昭衍新药（603127）披露H股及A股股本无变动情况，1月5日股价上涨10.0%
证券之星 · 01-05
昭衍新药（603127）披露H股及A股股本无变动情况，1月5日股价上涨10.0%
异动快报：昭衍新药（603127）1月5日10点53分触及涨停板
证券之星 · 01-05
异动快报：昭衍新药（603127）1月5日10点53分触及涨停板
港股医药股走强 昭衍新药涨近10%
南方财经网 · 01-05
港股医药股走强 昭衍新药涨近10%
每周股票复盘：昭衍新药（603127）实控人周志文拟减持不超1.99873%
证券之星 · 01-02
每周股票复盘：昭衍新药（603127）实控人周志文拟减持不超1.99873%
12月30日昭衍新药跌6.20%，广发小盘LOF基金重仓该股
证券之星 · 2025-12-30
12月30日昭衍新药跌6.20%，广发小盘LOF基金重仓该股
加载更多
公司概况
公司名称：
北京昭衍新药研究中心股份有限公司
所属行业：
研究和试验发展
上市日期：
2017-08-25
主营业务：
北京昭衍新药研究中心股份有限公司的主营业务是以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品是药物非临床研究服务、临床服务及其他、实验模型供应。
发行价格：
12.51
{"stockData":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":35.86,"timestamp":1770015600000,"preClose":38.01,"halted":0,"volume":17088651,"delay":0,"changeRate":-0.0566,"floatShares":630000000,"shares":749000000,"eps":0.3004,"marketStatus":"已收盘","change":-2.15,"latestTime":"02-02 15:00:00","open":37.02,"high":38.14,"low":35.86,"amount":629000000,"amplitude":0.06,"askPrice":35.87,"askSize":144,"bidPrice":35.86,"bidSize":731,"shortable":0,"etf":0,"ttmEps":0.3004,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770082200000},"marketStatusCode":5,"adr":0,"adjPreClose":38.01,"symbolType":"stock","openAndCloseTimeList":[[1769995800000,1770003000000],[1770008400000,1770015600000]],"highLimit":41.81,"lowLimit":34.21,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":749348220,"isCdr":false,"pbRate":3.31,"roa":"--","peRate":119.374168,"roe":"1.0%","epsLYR":0.1,"committee":0.434679,"marketValue":26872000000,"turnoverRate":0.0271,"status":1,"hkstockBrief":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":21.68,"timestamp":1770019686007,"preClose":24.32,"halted":0,"volume":7645007,"delay":0,"premium":"-46.28"},"floatMarketCap":22604000000},"requestUrl":"/m/hq/s/603127","defaultTab":"news","newsList":[{"id":"2608727350","title":"每周股票复盘：昭衍新药（603127）股东周志文减持1497.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608727350","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608727350?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:49","pubTimestamp":1769881750,"startTime":"0","endTime":"0","summary":"来自股本股东变化：股东周志文于2026年1月24日至28日合计减持487.53万股，占总股本0.6506%。交易信息汇总1月28日昭衍新药发生2笔大宗交易，成交金额8830.64万元。股本股东变化股东周志文于2026年1月24日至2026年1月28日间合计减持487.53万股，占公司目前总股本的0.6506%，变动期间该股股价下跌7.65%，截止1月28日收盘报37.93元。周志文决定提前终止减持计划，实际减持情况与披露计划一致，未违反相关承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK0216","BK1141","06127","603127"],"gpt_icon":0},{"id":"2607025472","title":"AI重塑医药生产力，为何超六成医药企业拥抱钉钉？","url":"https://stock-news.laohu8.com/highlight/detail?id=2607025472","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607025472?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:43","pubTimestamp":1769737380,"startTime":"0","endTime":"0","summary":"以“AI重塑医药生产力”为主题的2026医药钉峰会日前在沪召开，共探人工智能技术如何驱动赋能医药行业。AI自动完成数据抓取、分析与预警，让人人皆可成为开发者，大幅提升了业务响应的敏捷性。此外，AI正成为药企全球化协同的基石。AI不再是遥远的技术概念，而是已经成为医药行业提质、增效、创新的核心驱动要素。随着AI技术产品持续完善、行业生态日益繁荣，一场以人工智能为核心的医药生产力革命，正从蓝图加速照进现实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130095032a466dcda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130095032a466dcda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0819121731.USD","LU0708995153.HKD","LU0235996351.USD","BK1588","LU2778985437.USD","LU0823041008.USD","LU0823413660.USD","LU1051768304.USD","LU0264606111.USD","LU0320764599.SGD","LU0441854154.USD","BK1521","LU0543330566.HKD","LU0873338254.USD","LU0611395673.USD","LU0979878070.USD","LU0675040207.SGD","LU0516423174.USD","LU0127658192.USD","LU1719994722.HKD","LU0054237671.USD","SG9999004220.SGD","LU1720050803.USD","LU0329678337.USD","LU2328871848.SGD","LU0856984785.SGD","LU1048484197.HKD","LU0455707207.USD","SG9999000459.SGD","LU0577902454.USD","LU0784639295.USD","BK1615","LU2242644610.SGD","LU1831875114.USD","LU0348735423.USD","BK1517","LU0762540952.USD","02157","LU0417516738.SGD","LU0823039010.USD","LU2399975544.HKD","LU0577902538.SGD","LU0588545730.USD","LU3063872942.SGD","LU0828237510.HKD","LU1642822792.SGD","LU0143863198.USD","LU0181495838.USD","LU1880383440.USD","BK1608","LU0130518102.USD","BK1583","LU0054450605.USD","BK1610","LU0359201885.HKD","01276","LU0163747925.USD","LU0541502299.USD","LU0314109678.HKD","LU1282651048.USD","LU0449515922.USD","LU0865486749.SGD","LU0868486357.SGD","IE00B3M56506.USD","LU1880398471.USD","LU0831103253.SGD","LU1504937902.USD","LU1044876610.USD","LU0345776255.USD","LU1242518931.SGD","LU1769817179.HKD","LU0011963245.USD","LU0320764755.SGD","LU1282649810.SGD","LU0823397103.USD","LU2125910500.SGD","LU0327786744.USD","SG9999001093.SGD","LU0348788117.USD","LU0348827113.USD","LU1969619763.USD","LU1224444064.USD","LU2045819591.USD","LU0594300419.USD","LU1196710864.SGD","LU1956131251.USD","LU0287142896.SGD","LU0214875030.USD","89988","LU0251144936.SGD","LU1044875133.USD","LU2097828714.EUR","LU1188198961.HKD","LU0821914370.USD","LU0708995583.HKD","IE00B0JY6N72.USD","LU1316542783.SGD","LU1808992512.USD","LU0469268626.HKD","LU0106959298.USD","LU0823413587.USD","LU0164872284.USD","SG9999000327.SGD","LU0320764243.SGD","LU0588545904.SGD","06127","IE0032431581.USD","IE00B0169N27.USD","LU0890818403.SGD","LU0862451837.USD","LU2152927971.USD","LU0348783662.USD","LU0607220059.USD","BK1591","LU0164865239.USD","BK1501","LU0502904849.HKD","LU0572940350.SGD","LU1044874839.SGD","LU1481107354.HKD","LU0128522744.USD","LU1048596156.SGD","SGXZ90724238.SGD","LU1770036033.HKD","LU0499858602.USD","LU0210526637.USD","LU0128522157.USD","LU0516422366.SGD","601607","LU0886674414.USD","LU0029874905.USD","LU0823038988.USD","LU0417516571.SGD","IE0003895053.USD","LU0048580855.USD","LU1993786604.SGD","LU1282649141.HKD","LU0456846285.SGD","LU1023057109.AUD","09988","LU0871576103.HKD","LU1048588211.SGD","LU2097828631.EUR","LU0608807946.USD","LU1328615791.USD","LU0828237940.HKD","LU0051755006.USD","LU1794554557.SGD","LU1655091459.SGD","SG9999006514.SGD","LU0254981946.USD","LU0516422952.EUR","LU0348805143.USD","BK1142","BABA","LU0315178854.USD","LU1720051108.HKD","LU0449509016.USD","LU0737861699.HKD","LU0531971595.HKD","02607","LU1439103000.SGD","LU0831093199.SGD","LU0456827905.SGD","IE00B5MMRT66.SGD","LU0672654166.SGD","LU0516423091.SGD","LU0737861772.HKD","LU1981816686.USD","LU0231483743.USD","LU1115378108.SGD","BK1586","LU0307460666.USD","IE00B543WZ88.USD","LU1303224171.USD","LU2293587155.HKD","LU0577902611.USD","LU2097828474.EUR","SG9999002828.SGD","LU0540923850.HKD","LU0651946864.USD","BK1589","SG9999002463.SGD","LU0132412106.USD","LU1323998911.USD","IE00BZ08YR35.GBP","LU0823040885.USD","LU0762542818.HKD","BK1249","LU2449936058.SGD","000538","LU1051769294.HKD","LU1807302812.USD","LU1960683339.HKD","HK0000320223.HKD","LU0348783233.USD","LU0819123356.HKD","SG9999001689.USD","IE00BPRC5H50.USD","LU0164880469.USD","LU0048597586.USD","LU1211504680.USD","LU0700851271.USD","LU0169518387.USD","LU0359201612.USD","LU0608807433.USD","LU1201861165.SGD","LU0516422440.USD","SG9999001051.SGD","LU0173614495.USD","LU0149721374.USD","LU0499858438.USD","LU0293314216.USD","LU0463099449.HKD","LU2097829019.USD","BK1161","LU2087589342.USD","LU0593848301.USD","LU2476274720.SGD","LU1880398554.USD","LU0359202008.SGD","IE00BMPRXN33.USD","SG9999006597.SGD","HK0000320264.USD","LU0648948544.HKD","LU0117844026.USD","LU0096374516.USD","LU1548497426.USD","BK1618","LU1720051017.SGD","LU0029875118.USD","BK1515","LU0589944569.HKD","LU1961090484.USD","LU0228659784.USD","LU1282651121.HKD","LU2257852520.SGD","IE0034224299.USD","LU0348825331.USD","LU0577902371.SGD","LU0117841782.USD","LU0630378429.USD","LU0049853897.USD","LU0823397285.USD","LU0197773160.USD","LU0384037296.USD","LU1515016050.SGD","SG9999001226.SGD","IE00BZ08YT58.USD","LU0196878994.USD","LU0143863784.USD","LU0345775950.USD","LU0228367735.SGD","LU0052750758.USD","SG9999002562.SGD","LU0084288322.USD","LU1242518857.USD","LU0165289439.USD","LU0197773673.USD","01801","600276","LU0634319403.HKD","LU1366334578.USD","LU0244354667.USD","LU0259732245.USD","IE00BZ08YS42.EUR","IE00BMPRXR70.SGD","LU0149534421.HKD","LU0328353924.USD","LU0642271901.SGD","BK1574","LU0261950983.USD","BK1584","LU1224709979.USD","HK0000306701.USD","SHPMY","LU0588545490.SGD","LU0326950275.SGD","LU0640798160.USD","LU0762541174.USD","LU1770034418.SGD","HBBD.SI","LU0791591158.USD","LU0488056044.USD","LU0047713382.USD","LU2488822045.USD","SG9999014674.SGD","LU0862451753.SGD","LU0543330483.HKD","BK1575","LU0651947912.USD","LU0791590937.USD","LU0588546209.SGD","LU0210527791.USD","LU0211977185.USD","LU0048388663.USD","LU0431992006.USD","LU1568876335.HKD","SG9999001903.USD","LU0823426308.USD","LU0630378692.HKD","LU0261947096.USD","LU1880383366.USD","LU0561508036.HKD","LU0140636845.USD","LU1251922891.USD","LU1769817096.USD","LU1810669033.SGD","LU0417516902.SGD","LU0039217434.USD","LU0823426480.USD","LU0370786039.SGD","LU0061477393.USD","LU0898667661.SGD","LU2125910849.SGD","LU0531970944.HKD","LU0594300179.USD","LU0329678170.USD","LU1366334651.USD","LU0348784397.USD","LU0572939691.SGD","HK0000306685.HKD","LU1868837565.USD","LU2097828805.USD","LU2039709279.SGD","LU2097828557.USD","LU0572944931.SGD","LU1328277881.USD","LU1568876251.USD","HK0000165453.HKD","LU1688375341.USD","LU0106259558.USD","LU0541501648.USD","LU0229945570.USD","LU1282649067.USD","LU2357305700.SGD","LU0605514214.HKD","603127","IE0008368304.USD","LU0072462343.USD","LU0130103400.USD","ALBmain","LU0106252389.USD","LU0043850808.USD","LU2476274308.USD","LU1813983027.USD","LU1868838027.USD","LU0650527681.SGD","BK1502","LU0315179316.USD","LU0477156797.USD","LU0396098781.USD","LU0577902298.EUR","LU0648000940.SGD"],"gpt_icon":1},{"id":"2607806707","title":"昭衍新药：周志文已减持1497.90万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2607806707","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607806707?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:19","pubTimestamp":1769678358,"startTime":"0","endTime":"0","summary":"南财智讯1月29日电，昭衍新药公告，公司实际控制人之一周志文于2026年1月22日至1月28日通过集中竞价及大宗交易方式合计减持公司A股股份14,979,000股，占公司当前总股本的1.99894%，减持计划已提前终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635326997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06127","BK0216","BK1576","603127","BK1141"],"gpt_icon":0},{"id":"2606215319","title":"实验猴涨价推动昭衍新药业绩反转，预计2025年扣非净利同比增长超9倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2606215319","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606215319?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:23","pubTimestamp":1769419411,"startTime":"0","endTime":"0","summary":"1月21日，昭衍新药发布了2025年度业绩预告。公司预计实现营业收入约15.73亿元到17.38亿元，较2024年减少约13.9%到22.1%；实现净利润约2.33亿元到3.49亿元，较2024年增加约214%到371%；实现扣非净利润2.46亿元到3.70亿元，较2024年增加约945.2%到1467.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601263630730329.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601263630730329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","BK1576","06127","BK0216","603127"],"gpt_icon":0},{"id":"2606234770","title":"每周股票复盘：昭衍新药（603127）股东周志文减持1010.37万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606234770","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606234770?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:09","pubTimestamp":1769278150,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，昭衍新药报收于41.07元，较上周的42.03元下跌2.28%。交易信息汇总1月23日昭衍新药发生2笔大宗交易，合计成交2.13亿元，折价12.81%。股本股东变化股东增减持1月23日，昭衍新药公告股东周志文于2026年1月22日至23日合计减持1010.37万股，占公司总股本1.3483%。北京昭衍新药研究中心股份有限公司于2026年1月23日收到实际控制人周志文减持股份通知。本次权益变动后，周志文及冯宇霞合计持股比例由32.27%降至30.93%，触及1%权益变动刻度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK1141","BK1576","06127","603127"],"gpt_icon":0},{"id":"2605757184","title":"1月23日昭衍新药现2笔折价12.81%的大宗交易 合计成交2.13亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605757184","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605757184?lang=zh_cn&edition=full","pubTime":"2026-01-23 17:49","pubTimestamp":1769161772,"startTime":"0","endTime":"0","summary":"证券之星消息，1月23日昭衍新药发生大宗交易，交易数据如下：近三个月该股共发生2笔大宗交易，合计成交5.95万手，折价成交2笔。该股近期无解禁股上市。截至2026年1月23日收盘，昭衍新药报收于41.07元，上涨3.24%，换手率3.33%，成交量20.98万手，成交额8.67亿元。该股近半年内有股东持股变动，合计净减持226.49万股，股东增减持明细如下表：该股最近90天内共有6家机构给出评级，买入评级5家，增持评级1家；过去90天内机构目标均价为40.13。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300029915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","06127","603127","BK1141","BK1576"],"gpt_icon":0},{"id":"2605491486","title":"去年四季度买回昭衍新药、中国东航，中欧基金葛兰：一季度医药板块有望延续结构性行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2605491486","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605491486?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:14","pubTimestamp":1769087660,"startTime":"0","endTime":"0","summary":"2025年末，中欧基金投资总监葛兰在管基金总规模缩水至“300亿元”梯队。1月22日，据最新披露的2025年四季报，葛兰旗下在管基金总规模由去年三季度末的435.44亿元降至去年四季度末的353.89亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601223627662712.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627662712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0010","BK0164","09939","BK0020","BK1161","BK0183","BK0028","BK1515","BK0188","BK0196","BK1141","06127","BK0280","159938","BK0216","BK0012","BK1576","BK0006","BK0053","603127","600115","BK1574"],"gpt_icon":0},{"id":"2605103044","title":"富贵猴中求？实验猴价格涨至15万元一只，昭衍新药净利润预增超214%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605103044","media":"时代财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605103044?lang=zh_cn&edition=full","pubTime":"2026-01-21 18:26","pubTimestamp":1768991173,"startTime":"0","endTime":"0","summary":"1月20日晚，CRO公司昭衍新药（603127.SH，06127.HK）发布年度业绩预告称，公司预计2025年实现归属于上市公司股东的净利润约2.33亿元到3.49亿元，同比增加约214.0%到371.0%。对于净利润上涨的原因，昭衍新药在公告中指出，本报告期内，生物资产市场价格上涨叠加自身自然生长增值，双重因素驱动其公允价值正向变动，为公司业绩做出积极贡献。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601213626185160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603127","06127"],"gpt_icon":0},{"id":"2604192180","title":"昭衍新药：公司具备OECD的GLP认证资质，可以承接相关非临床服务项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2604192180","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604192180?lang=zh_cn&edition=full","pubTime":"2026-01-20 19:09","pubTimestamp":1768907385,"startTime":"0","endTime":"0","summary":"证券日报网讯1月20日，昭衍新药在互动平台回答投资者提问时表示，公司具备OECD的GLP认证资质，可以承接相关非临床服务项目，但来自欧盟地区的收入占比极低，不构成重要影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624853333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4590","BK0216","06127","603127","BK4144","BK1576","BK1141","GLP"],"gpt_icon":0},{"id":"2604193087","title":"昭衍新药：2025年净利同比预增214%~371%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604193087","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604193087?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:57","pubTimestamp":1768899433,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月20日，昭衍新药(603127.SH)发布2025年度业绩预告，预计归属于上市公司股东的净利润为2.33亿元~3.49亿元，比上年同期增长214.0%~371.0%。报告期内，生物资产市场价格上涨叠加自身自然生长增值，驱动公允价值正向变动，对业绩产生积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601203624727291.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624727291.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","BK1576","BK1141","06127","603127"],"gpt_icon":0},{"id":"2603684947","title":"昭衍新药：公司不涉及脑机接口业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2603684947","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603684947?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:09","pubTimestamp":1768309754,"startTime":"0","endTime":"0","summary":"证券日报网讯1月13日，昭衍新药在互动平台回答投资者提问时表示，公司非人灵长类模型主要是自用，用于非临床安评实验相关研究，不涉及脑机接口业务，相关信息请以公司披露的相关公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617665796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","BK1141","BK1576","603127","06127"],"gpt_icon":0},{"id":"2602535959","title":"每周股票复盘：昭衍新药（603127）拟注销129,114股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535959","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535959?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:47","pubTimestamp":1768070828,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：昭衍新药拟注销129,114股A股股份，总股本将相应减少。公司公告汇总H股公告：12月月报表北京昭衍新药研究中心股份有限公司提交截至2025年12月31日的证券变动月报表，报告显示公司H股和A股的法定/注册股本、已发行股份及库存股数量均无变动。昭衍新药关于员工持股计划回购股份注销实施公告北京昭衍新药研究中心股份有限公司因终止实施2021年及2022年A股员工持股计划，拟注销回购专用账户中合计129,114股A股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","06127","603127","159982","399300","BK1576","BK1141"],"gpt_icon":0},{"id":"2602347895","title":"港股异动 | 昭衍新药(06127)涨超7% 近一月股价累涨近六成 公司有望受益猴价公允价值收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2602347895","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602347895?lang=zh_cn&edition=full","pubTime":"2026-01-09 14:49","pubTimestamp":1767941364,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药再涨超7%，近一月股价累涨近六成。截至发稿，涨7.02%，报25.92港元，成交额2.03亿港元。据方正证券测算，以昭衍新药为例，假设按照2024年实验猴均价计入公允价值8.49万/只，2025Q4价格提升至14万/只，假设猴场出栏率为17%，按照已知23200只猴测算，毛估计2025年新增公允价值约2.2亿。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","603127","06127","BK1141","BK1576"],"gpt_icon":0},{"id":"2601339124","title":"港股异动 | 昭衍新药(06127)再涨超4% 实验猴供需缺口或不断拉大 公司拥有优质稀缺实验猴资源","url":"https://stock-news.laohu8.com/highlight/detail?id=2601339124","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601339124?lang=zh_cn&edition=full","pubTime":"2026-01-08 10:59","pubTimestamp":1767841147,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药再涨超4%，截至发稿，涨3.36%，报24港元，成交额1.08亿港元。长江证券发布研报称，当前，实验猴供给端不断下降，需求端企稳回升以及新技术如小核酸、CAR-T 等大多也需要使用实验猴带来的结构化占比提升，实验猴供需缺口或正不断拉大，猴价也开始呈现上升趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","603127","BK0216","BK1141","BK1576"],"gpt_icon":0},{"id":"2601180738","title":"昭衍新药（603127）披露员工持股计划回购股份注销实施公告，1月6日股价下跌0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601180738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601180738?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:09","pubTimestamp":1767708560,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，昭衍新药报收于38.45元，较前一交易日下跌0.16%，最新总市值为288.17亿元。该股当日开盘39.8元，最高39.96元，最低37.8元，成交额达13.08亿元，换手率为5.37%。公司近日发布公告称，北京昭衍新药研究中心股份有限公司因终止实施2021年及2022年A股员工持股计划，拟注销回购专用账户中合计129,114股A股股份。该事项已履行董事会、股东大会审议程序，并完成债权人通知程序。本次注销股份将于2026年1月7日实施，公司总股本将由749,477,334股变更为749,348,220股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK1576","BK1141","06127","603127"],"gpt_icon":0},{"id":"2601002067","title":"昭衍新药（603127）披露H股及A股股本无变动情况，1月5日股价上涨10.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601002067","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601002067?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:42","pubTimestamp":1767606170,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，昭衍新药报收于38.51元，较前一交易日上涨10.0%，最新总市值为288.62亿元。公司近日发布公告称，北京昭衍新药研究中心股份有限公司已提交截至2025年12月31日的证券变动月报表。公告显示，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股于香港联交所上市，证券代码06127；A股于上海证券交易所上市，证券代码603127。已发行H股118,995,206股，A股627,179,094股，库存股3,303,034股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500025712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","159982","BK1141","399300","BK1576","603127","BK0216"],"gpt_icon":0},{"id":"2601797130","title":"异动快报：昭衍新药（603127）1月5日10点53分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2601797130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601797130?lang=zh_cn&edition=full","pubTime":"2026-01-05 10:55","pubTimestamp":1767581719,"startTime":"0","endTime":"0","summary":"证券之星1月5日盘中消息，10点53分昭衍新药触及涨停板。其所属行业医疗服务目前上涨。领涨股为三博脑科。该股为基因编辑，干细胞，AI医疗概念热股，当日基因编辑概念上涨4.47%，干细胞概念上涨4.05%，AI医疗概念上涨3.75%。12月31日的资金流向数据方面，主力资金净流出5814.26万元，占总成交额9.85%，游资资金净流入1665.91万元，占总成交额2.82%，散户资金净流入4148.35万元，占总成交额7.03%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500008901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","06127","BK1141","603127","BK0216"],"gpt_icon":0},{"id":"2601793240","title":"港股医药股走强 昭衍新药涨近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601793240","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601793240?lang=zh_cn&edition=full","pubTime":"2026-01-05 10:24","pubTimestamp":1767579852,"startTime":"0","endTime":"0","summary":"南方财经1月5日电，港股医药股走强，截至发稿，昭衍新药(06127.HK)涨9.72%、泰格医药(03347.HK)涨5.94%、康龙化成(03759.HK)涨3.68%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601053608528139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159718","06127","BK0216","BK1576","BK1141","603127"],"gpt_icon":0},{"id":"2600842035","title":"每周股票复盘：昭衍新药（603127）实控人周志文拟减持不超1.99873%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600842035","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600842035?lang=zh_cn&edition=full","pubTime":"2026-01-02 01:23","pubTimestamp":1767288189,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，昭衍新药报收于36.94元，较上周的35.42元上涨4.29%。本周，昭衍新药12月25日盘中最高价报37.89元。12月22日盘中最低价报34.46元。昭衍新药当前最新总市值262.39亿元，在医疗服务板块市值排名6/51，在两市A股市值排名753/5181。减持原因为自身资金需求，减持价格将根据市场价格确定。本次减持不会导致公司控制权变更，且符合相关法律法规及此前承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK0216","BK1141","06127","603127"],"gpt_icon":0},{"id":"2595762310","title":"12月30日昭衍新药跌6.20%，广发小盘LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595762310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595762310?lang=zh_cn&edition=full","pubTime":"2025-12-30 15:32","pubTimestamp":1767079952,"startTime":"0","endTime":"0","summary":"证券之星消息，12月30日昭衍新药跌6.20%，收盘报34.8元，换手率5.23%，成交量33.0万手，成交额11.47亿元。重仓昭衍新药的前十大公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级5家，增持评级1家；过去90天内机构目标均价为40.13。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共19家，其中持有数量最多的公募基金为广发基金的广发小盘LOF。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000020196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK1141","603127","BK1576","06127","162703"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770043636930,"stockEarnings":[{"period":"1week","weight":-0.0745},{"period":"1month","weight":0.0857},{"period":"3month","weight":0.0276},{"period":"6month","weight":0.1793},{"period":"1year","weight":1.3659},{"period":"ytd","weight":0.0857}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0376},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.1567},{"period":"1year","weight":0.2668},{"period":"ytd","weight":0.0376}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京昭衍新药研究中心股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2017-08-25","address":"北京市大兴区北京经济技术开发区荣京东街甲5号","registeredCapital":"74934万元","survey":" 北京昭衍新药研究中心股份有限公司的主营业务是以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品是药物非临床研究服务、临床服务及其他、实验模型供应。","listedPrice":12.51},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,603127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}